4 documents found, page 1 of 1
The global NAFLD policy review and preparedness index: are countries ready to a...
Lazarus, Jeffrey V.; Mark, Henry E.; Villota-Rivas, Marcela; Palayew, Adam; Carrieri, Patrizia; Colombo, Massimo; Ekstedt, Mattias; Esmat, GamalBackground & aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods: We collected data from 102 countries, accounting for 86% of the world population, on NAFLD pol...
Defining comprehensive models of care for NAFLD
Lazarus, Jeffrey V.; Anstee, Quentin M.; Hagström, Hannes; Cusi, Kenneth; Cortez-Pinto, Helena; Mark, Henry E.; Roden, Michael; Tsochatzis, Emmanuel A.Non- alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease globally. Despite the increased demand placed on health- care systems, little attention has been given to the design and implementation of efficient and effective models of care for patients with NAFLD. In many health- care settings, no formal pathways exist and, where pathways are in place, they are often not standardi...
Advancing the global public health agenda for NAFLD: a consensus statement
Lazarus, Jeffrey V.; Mark, Henry E.; Anstee, Quentin M.; Arab, Juan Pablo; Batterham, Rachel L.; Castera, Laurent; Cortez-Pinto, Helena; Crespo, JavierNon-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attentio...
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim an...
Younossi, Zobair M.; Ratziu, Vlad; Loomba, Rohit; Rinella, Mary; Anstee, Quentin M.; Goodman, Zachary; Bedossa, Pierre; Geier, AndreasBackground: Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods: In this multicentre, randomised, double-blind, placebo-contro...